ABSTRACT
INTRODUCTION
Gorham-Stout syndrome (GSS) is an uncommon disease firstly described by Jackson in 1838 as a clinical condition characterized by massive osteolysis. In 1955 Gorham and Stout refered to this disease as disappearing bone, caused by excessive bone resorption associated with apparently nonmalignant proliferation of blood or lymphatic vessels [1] . This syndrome can develop in males and females of any race and any age, indeed the youngest patient reported is one month old and the oldest one is 75 years old. Clinical presentation is very inconstant, depending on the number and the localization of the lesions. Generally, it is characterized by pain, functional impairment and swelling, but it can be asymptomatic until a pathologic fracture. Radiological features of bone vary from patchy osteoporosis to fractures or complete resorption. Definitve diagnosis is achieved perfoming a histopathological analysis of the lesions that reveals nonmalignant hyperproliferation of small vessels. Although this disease is considered benignant, the prognosis can be very poor. Complications of this disease include pleural effusion, that can seriously impair respiratory function [2] . Few cases are reported about pleural effusion in Gorham-Stout syndrome. We present a case with bilateral serohematic pleural effusion and a revision of the literature regarding GSS associated with pleural effusion. Our intent is to better define the clinical presentation and the prognosis of the patients presenting pleural effusion in GSS, assessing the most successful treatment of this complication.
CASE REPORT
A 46 year old man was admitted to our division for bilateral pleural effusion in October 2010.
Clinically he claimed ingravescent dyspnea and persistent thoracic pain in correspondence of manubrium lasting for 3 weeks. The patient was treated with Levothyroxin for previous thyroidectomy, performed for papillary thyroid cancer. Blood examination was normal, fever was absent. Chest CT showed abundant bilateral pleural effusions more extended on the left side and compressive lung consolidation at the bases without lymphadenopathies. It was also apparent a lytic lesion of the manubrium sterni involving the first right chondrosternal and the left sternoclavicular joints. Chest ultrasound displayed bilateral complex nonseptated pleural effusion with hematocrit sign (figure 1).
Initially we decided to position a right thoracic tube and 2000 ml of serohematic liquid were drained. Cytological examination resulted negative for neoplastic cells. In the next days the tube continued to drain conspicuous pleural liquid, then we decided to perform a medical thoracoscopy (MT) without pleurodesis on the contralateral side. Parietal pleura appeared diffusely thick and hyperemic, without any other lesions ( figure 2-3) . Every specimen obtained during the pleuroscopy resulted in nonspecific pleural inflammation.
We performed also an ago-biopsy of the osteolytic lesion that revealed only fibrotic areas.
Then we executed a positron emission tomography (PET) to look for any other lesions. It confirmed the presence of the known injury of the manubrium without other pathological alterations except for a diffuse pleural enhancement. Since the patient felt better, although all our diagnostic tests resulted not conclusive, he was discharged, waiting before any other further investigations.
Because of perpetual bilateral pleural effusions, after two months we decided to admit another time the patient. The clinical scenario was similar to that one of the previous admission. This time we performed a MT on the right side. The examinations on the specimens obtained results resulted identical to that performed previously. However this time talc poudrage was carried out.
At this stage we were able to exclude any pleural diseases (bilateral MT), a thyroid cancer recurrence or any other primitive cancers (PET), but we could not explain pathological process underlying the osteolytic area of the manubrium. Thus, although the previous ago-biopsy resulted negative, we decided for surgical excision of this lesion. A large biopsy was collected with osseous, cartilaginous and muscular tissue. Microscopic evaluation showed osteolysis areas with proliferation of mainly blood and more rarely lymphatic vessels. A collegial discussion with pathologists let us to reach the correct diagnosis. Considering that the lesion was already totally cut off surgically and that there was no evidence of other localizations, we decided to radicalize the treatment with local radiation therapy. No other treatment was applied.
Radiological and sonographic follow-up showed no recurrence until March 2015 (more than 4 years from the diagnosis), when a chest x-ray showed moderate right pleural effusion and left basal hydropneumothorax associated to 3 rd rib irregularity and contiguous soft tissue thickening.
Despite these radiological findings, the patient was asymptomatic and no diagnostic investigations or treatment were performed, continuing only follow up.
DISCUSSION AND LITERATURE REVIEW
Gorham-Stout syndrome (GSS) is a rare disorder characterized by osteolysis [1] . The typical anatomopathological pattern is bone resorption due to proliferation of blood and lymphatic vessels. It can involve different bones, even with multiple localizations and it can spread to the adjacent tissue. Definitive diagnosis is obtained with histological examination of the lesions that reveals proliferation of blood and lymphatic vessels causing bone resorption. Until now the exact pathogenetic mechanism is not elucidated so it remains an idiopathic disease. Rarely GSS can induce pleural effusion. We reviewed the literature in order to clarify epidemiology, clinical characteristics and therapies of pleural effusion in GSS. We carried out a revision of all clinical cases present in English language literature (Medline Pubmed) regarding pleural effusion secondary to GSS. Pleural effusion is a very rare presentation in GSS, indeed we founded only 51 clinical cases reported 3 ones were excluded from this work because the pleural effusion was presumably secondary to the surgical procedure [42, 47, 48] Our analysis of the literature shows that the pathogenesis of pleural effusion in GSS is not yet established. In fact in our clinical case with serohematic pleural effusion, although the GSS lesion involve a bone adjacent to the parietal pleura, bilateral medical thoracoscopies showed only a diffuse non-specific pleural inflammation. Also in the other case of serohematic pleural effusion, studied with thoracotomy, the macroscopic observation and the microscopic analysis of pleura specimens did not display abnormal proliferation of blood vessels, the typical lesions of GSS, but only chronic inflammation [11] . Thus the etiopathogenesis of serohematic pleural effusion production in GSS is not clarified. We can only suppose an indirect involvement of the pleura in the pathological process. In a limited number of cases with chylothorax, lymphangiography showed a disruption of the normal architecture of the thoracic duct that appeared enlarged and convoluted [3, 29] . Moreover in other cases, a proliferation of lymphatic vessels was demonstrated in histological specimens of the pleura [15-18, 22, 26, 29, 31, 39] . Sometimes the bone lesions are localized remote from the chest [7, 16, 21, 39] in these cases the pathogenetic mechanisms of chylothorax is completely unknown and an undefined systemic process damaging the thoracic duct or other lymphatic vessels can be only supposed. Further studies will be needed to elucidate this aspect.
Clinically it resulted that pleural effusion in GSS is most of time localized bilaterally or on the right side (41% and 33% respectively) (table 2). Often the symptom at the onset of the disease is represented by ingravescent dyspnea secondary to abundant pleural effusion that limits the lung expansion. Due to the frequent young age of the patients, the peripheral oxyhemoglobin saturation normally is not severely compromised at the beginning. More rarely, GSS with pleural effusion can start with chest pain associated or not with dyspnea (table 2). At times, particularly when the pathologic process involves the bones of limbs, a pathological fracture can be the first sign of disease [21] . Most of the time pleural effusion in GSS requests several thoracentesis or a chest drainage inserction by the reason of quick relapses. Even several liters of chylous liquid can be produced in a few days conditioning malnutrition [9, 12, 26, 27, 30, 32] . Frequently this complication necessitates a rapid parenteral nutritional support and human albumin replacement.
When pleural effusion is unilateral it can conduce to mediastinal shift if it is not treated promptly [35] . Considering the little number of cases described to date, there are no standard therapies for pleural effusion caused by Gorham disease. In table 1 the different treatment and the clinical outcome are scheduled. Our examination of literature suggests that systemic drugs are the most frequent treatment. In particular bisphosphonates and alpha-2b interferon (IFN -2b) [14] seem to be the most effective because they can control directly the multiple bone lesions. It is known that bisphosphonates modulate osteoclasts activity, that is the most important responsible of the bone resorption. It has been observed that bisphosphonates regulate osteoclastic regulators osteoprotegerin (OPG) and free soluble RANKL serum concentrations [49] . OPG and RANKL have opposite functions, particularly RANKL promotes osteoclasts activity with bone resorption and OPG contrasts the linkage of RANKL with its receptor. During the treatment with bisphosphonates, serum dosages of OPG increase while the level of soluble RANKL drop with an increase of OPG/RANKL ratio and a subsequent imbalance towards osteoblastic activity [50] .
Moreover it is known that RANKL expression is stimulated by IL-6 that is considered to be implicated in the pathogenetic mechanism of this disease. Indeed the serum IL-6 levels are elevated in the patients affected by GSS but they decrease after treatment with bisphosphonates [49, 51] . The other drug used in GSS is IFN -2 because of its anti-angiogenic effect even if the exact mechanism is not completely understood. It has been observed that, although stimulates the release of IL-6 within a few hours from a single administration [52] when this drug is chronically applied to a patient with GSS it produces a clinical and radiological remission of the bone lesions. Pleural effusion in GSS can be controlled by surgical, medical or radiation approaches and frequently more than one is needed in the same patient. Thoracic duct reconditioning can be achieved by surgical ligation or by diathermy. These procedures should be applied only after a lymphographic study that demonstrates the thoracic duct leakage. In fact, the thoracic duct ligation should be performed only when the site of the leakage of the lymphatic vessel is accurately localized during the surgical procedure. In some cases this surgical management could not be carried out because the seepage is not recognized. An alternative approach consists in the administration of octreotide, a somatostatin synthetic analogue that can seal the lymphatic leakage [53] . This medical strategy can be performed even in absence of the direct localization of the leakage.
Our review demonstrates a large employment of radiation therapy (RT). It can be used on the bone lesions in order to consolidate the weakness of the bone tissue. In fact GSS is frequently related to pathologic fractures. Often this is the first clinical manifestation of the disease.
Moreover RT seems to be able to eradicate directly the pathological process contrasting the vessel proliferation. Furthermore it is useful to stop pleural effusion production when it is performed on the mediastinum, probably because it can heal the lymphatic system. In our opinion, this procedure seems to be more successful than the approaches described previously, also considering that it can be performed even without a lymphographic study. Thus a larger number of patient can be treated with RT compared to surgical approaches. Moreover RT can operate on an extended area; this vantage allows to treat at the same time different areas potentially involved by the disease in the mediastinum. In order to control pleural effusion, pleurodesis can be performed. Several modalities have been founded. The most applied method is the use of talc. Talc poudrage is a standard procedure that can be easily carried out during thoracoscopy or thoracotomy. In our opinion, it is little more favorable than the talc slurry that can be more easily performed injecting a dispersion of talc in a sterile normotonic saline solution through a chest drainage. In our experience, we performed a talc poudrage during MT on a single side with good results. Other Authors proposed to use a relatively new drug: Picibanil, also called OK-432. It is a lyophilized mixture of group A Streptococcus pyogenes: like talc it should be able to produce pleurodesis eliciting fibrosis. Instead, the surgical approach is represented by pleural decortication that is obviously characterized by larger complications. In this case we are not able to indicate the best modality.
Finally, when the lesion is single and early diagnosed, a surgical excision can be performed.
This way can be useful even to obtain the diagnosis, like in our experience. Moreover, we believe that the use of steroid in these patients is controversial; to date we are not able to understand the pathogenic mechanism of its employment.
In the case reports considered mean follow up time was limited to 2.0 years (SD ± 1.86). It is important to underline that clinical outcome was not specified in all papers. However, focusing only on the available data it resulted that almost 2/3 patients had no recurrences after the treatment, but more or less 30% of the patients died despite the clinical effort. The ingravescence of the disease is documented only in 2 cases.
CONCLUSION
Our review about the cases of GSS with a pleural involvement suggests that the treatment options are various. Frequently they need to be associated in a multimodality approach. Moreover the clinical scenarios are very heterogeneous with a large range of age and a large variability of symptoms. The little number and the variability of the cases reported prevent to identify a widely approved therapeutic strategy. This is a very serious disease caracterized by a poor prognosis in 1/3 patients, thus it is important to achieve the diagnosis quickly, starting the most suited treatment for the patient. 
